Refine
Has Fulltext
- yes (68)
Is part of the Bibliography
- yes (68)
Year of publication
- 2021 (68) (remove)
Document Type
- Journal article (53)
- Doctoral Thesis (15)
Keywords
- Aspergillus (5)
- Multiples Myelom (4)
- cytokines (4)
- inflammation (4)
- multiple myeloma (4)
- COVID-19 (3)
- T cells (3)
- biomarker (3)
- immunoassay (3)
- immunotherapy (3)
- Aspergillus fumigatus (2)
- Dendritische Zelle (2)
- Hepatozelluläres Karzinom (2)
- Leberzellkrebs (2)
- Monoklonaler Antikörper (2)
- Monoklonaler bispezifischer Antikörper (2)
- Multiple myeloma (2)
- SARS-CoV-2 (2)
- adaptive immunity (2)
- adoptive cell therapy (2)
- alloreactive T cells (2)
- lenalidomide (2)
- monoclonal antibody (2)
- mouse models (2)
- myeloma (2)
- therapeutic drug monitoring (2)
- toxicity (2)
- tumour immunology (2)
- 13C-Methacetin-Atemtest (1)
- 4-1BB Agonist (1)
- 4-1BB agonist (1)
- AML (1)
- ATTRv amyloidosis (1)
- Adhärenz (1)
- Aiolos (1)
- Antigen CD137 (1)
- Antigen CD40 (1)
- Antikörper-Fusionsproteine (1)
- Antikörpertherapie (1)
- B-Zell-Lymphom (1)
- BCOR (1)
- BCORL1 (1)
- BON-1 (1)
- Biologika (1)
- Brustkrebs (1)
- Bruton's tyrosine kinase inhibitor CC-292 (1)
- CAR T (1)
- CAR T-cell (1)
- CAR-T-cell (1)
- CD319 (1)
- CD38 (1)
- CD40 agonist (1)
- CMV (1)
- CMV-specific cellular immunity (1)
- CNS cancer (1)
- CRISPR/Cas9 (1)
- CS1 (1)
- CXCR4 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- Capecitabin (1)
- Checkpoint-Inhibitor (1)
- Compliance (1)
- Compliance <Patient> (1)
- Crohn’s Disease (1)
- DC (1)
- DSMM XIV (1)
- ELISPOT (1)
- Eisenhomöostase (1)
- Fractalkin (1)
- GCA (1)
- GDF (1)
- GDF-15 (1)
- Generalisierte Angststörung (1)
- German Hepatitis C-Registry (1)
- Grave’s disease (1)
- GvHD (1)
- HCV cure (1)
- HEV (1)
- Heavy Light Chain Assay (1)
- Helicobacter pylori (1)
- Helicobacter pylori eradication (1)
- Helicobacter-pylori-Eradikation (1)
- Hepatitis E (1)
- Hypoxie (1)
- IFN-γ ELISpot (1)
- IKZF1 (1)
- IKZF3 (1)
- IRF4 (1)
- Ikaros (1)
- Immunassay (1)
- Immunglobuline (1)
- Immunoassay (1)
- Immunoglobulins (1)
- Klonale T-Zellen (1)
- Kohlenstoff-13-Exhalationstest (1)
- LEOSS (1)
- Leberfunktion (1)
- Leberversagen (1)
- Leberzirrhose (1)
- Lenalidomid (1)
- Lichtheimia (1)
- Lymphom (1)
- MALT-Lymphom (1)
- MALT-Lymphoma (1)
- MS-18 (1)
- Magenlymphom (1)
- Mammakarzinom (1)
- Medication-related osteonecrosis of the jaw (1)
- Medikamenten-assoziierte Kiefernekrose (1)
- Megakaryopoese (1)
- Mikrosomale Leberfunktion (1)
- Minimal residual disease (1)
- Minimale Resterkrankung (1)
- NA (1)
- NET (1)
- NFAT (1)
- NK cell (1)
- NK-DC cross-talk (1)
- Nachsorge (1)
- Natürliche Killerzelle (1)
- Non-Hodgkin-Lymphom (1)
- PMR (1)
- PU.1 (1)
- Patientencompliance (1)
- Plasmide (1)
- Plasmozytom (1)
- Punktmutation (1)
- QGP-1 (1)
- RNS-Interferenz (1)
- Resistenz (1)
- Rheumatoide Arthritis (1)
- Ruxolitinib (1)
- SLAMF7 (1)
- Score (1)
- Sjögren’s syndrome (1)
- T-LGL-Leukämie (1)
- T-LGL-Zellen (1)
- T-Lymphozyt (1)
- T-Zellen (1)
- T-cell transfer (1)
- TNRSF (1)
- TTR knockdown (1)
- TTR stabilization (1)
- Th17 (1)
- Th9 (1)
- Transarterielle Chemoembolisation (1)
- Tumor-Nekrose-Faktor <alpha-Inhibitor> (1)
- VLA-1 (1)
- Waldeyer’s tonsillar ring (1)
- Wnt (1)
- [18F]FDG PET/CT (1)
- [\(^{68}\)Ga] Pentixafor (1)
- actin (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adherence (1)
- afatinib (1)
- allogeneic stem cell transplantation (1)
- amyloid‐directed antibodies (1)
- androgen deprivation therapy (1)
- antibody (1)
- antigen loss (1)
- antigen processing and presentation (1)
- antigens (1)
- aspergillosis (1)
- autoantibodies (1)
- autogenous jejunum transplantation (1)
- autoimmune disease (1)
- axi-cel (1)
- beta-D-glucan (1)
- biological fluorescence (1)
- bone adaptation (1)
- bortezomib (1)
- calcofluor white staining (1)
- cancer (1)
- cancer genetics (1)
- cancer genomics (1)
- cancer of unknown primary (CUP) (1)
- cancer therapy (1)
- cancer vaccine (1)
- cancer-induced bone disease (1)
- case report (1)
- chronic hepatitis C (1)
- chronic kidney disease (1)
- clinical study (1)
- cluster of differentiation (1)
- common variable immunodeficiency (CVID) (1)
- comorbidities (1)
- corticosteroids (1)
- critically ill patients (1)
- cytogenetics (1)
- cytokine therapy (1)
- cytomegalovirus (1)
- dendritic cells (1)
- dendritische Zellen (1)
- direct-acting antivirals (1)
- efficacy (1)
- elotuzumab (1)
- endoscopic full thickness resection (eFTR) (1)
- endoscopic vacuum therapy (1)
- engraftment syndrome (1)
- esophageal fistula (1)
- esophageal perforation (1)
- esophageal stenosis (1)
- extramedullary (1)
- extramedullary disease (1)
- familial amyloid polyneuropathy (FAP) (1)
- fatty liver disease (1)
- fever (1)
- flow cytometry (1)
- fluorescence imaging (1)
- follow-up (1)
- frail (1)
- free-jejunal graft (1)
- full-thickness resection device (FTRD) (1)
- fungal infection model (1)
- gRNA-only (1)
- galactomannan (1)
- gastric MALT lymphoma (1)
- gastric fistula (1)
- gene therapy (1)
- genital warts (1)
- giant cell arteritis (1)
- graft versus host disease (1)
- hematology (1)
- hematopoietic stem cell transplantation (1)
- hemolytic anemia (1)
- homing (1)
- host defense (1)
- host-pathogen interaction (1)
- human papillomavirus (1)
- hypersensitivity (1)
- ileocecal resection (1)
- imaging the immune system (1)
- immune checkpoint inhibitor (1)
- immune monitoring (1)
- immunohistochemistry (1)
- immunosuppression (1)
- in vitro models (1)
- inborn errors of immunity (IEIs) (1)
- induction regimen (1)
- infectious diseases (1)
- interferon-free (1)
- interleukin-9 (1)
- iron responisve element (1)
- kidney (1)
- kidney cancer (1)
- kinase inhibitors (1)
- large B-cell lymphoma (1)
- large granular lymphocyte (1)
- lasso regression (1)
- lenalidomide-refractory patients (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- loss-of-function (1)
- lymph node metastases (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- mTOR (1)
- machine learning (1)
- mechanical loading (1)
- mesenteric lymph node (1)
- metabolism (1)
- metastasis-directed therapy (1)
- microphysiological systems (1)
- mitochondrial DNA (1)
- modified Rodnan skin score (mRSS) (1)
- mold exposure (1)
- mtDNA (1)
- myeloid-derived suppressor cells (MDSCs) (1)
- naive T-cell gene editing (1)
- neuralgic amyotrophy (1)
- neuroendocrine tumor (1)
- neuroendocrine tumor (NET) (1)
- nomogram (1)
- oligmometastases (1)
- oligorecurrence (1)
- oncolytic viruses (1)
- orale Chemotherapie (1)
- osimertinib (1)
- paediatric cancer (1)
- pan-RCC (1)
- pancreatic head cancer (1)
- patients with multiple myeloma (1)
- pediatric (1)
- peptide (1)
- plasma cell disorder (1)
- plasma cells (1)
- polymyalgia rheumatica (1)
- pomalidomide (1)
- positron emission tomography/computed tomography (1)
- prediction (1)
- predictive factor (1)
- primary biliary cholangitis (1)
- primary immunodeficiency (1)
- prolonged cytopenia (1)
- prostate cancer (1)
- psoriasis (1)
- radiation therapy (1)
- real-time PCR (1)
- recall antigen (1)
- rectum (1)
- renal failure (1)
- rheumatoid arthritis (1)
- risk factors (1)
- risk stratification (1)
- risk factor analysis (1)
- scleroderma (1)
- second line therapy (1)
- silkworm (1)
- skeletal mechanobiology (1)
- spleen (1)
- stereotactic body radiotherapy (1)
- super-resolution microscopy (1)
- surgical therapy (1)
- survival (1)
- transanal endoscopic microsurgery (TEM) (1)
- translational research (1)
- transplantation (1)
- transthyretin (1)
- treatment response (1)
- tumor-on-chip (1)
- ursodeoxycholic acid (1)
- vasculature (1)
- vasculitis (1)
- weight gain (1)
- β-catenin (1)
Institute
- Medizinische Klinik und Poliklinik II (68) (remove)
According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration >10% and <60%, and absence of any myeloma-defining event. Active multiple myeloma is preceded by SMM, with a median time to progression of approximately 5 years. Cases of SMM range from the extremes of “monoclonal gammopathy of undetermined significance-like”, in which patients never progress during their lifetimes, to “early multiple myeloma”, in which transformation into symptomatic disease, based on genomic evolution, may be rapid and devastating. Such a “split personality” makes the prognosis and management of individual patients challenging, particularly with regard to the identification and possible early treatment of high-risk SMM. Outside of clinical trials, the conventional approach to SMM generally remains close observation until progression to active multiple myeloma. However, two prospective, randomized trials have recently demonstrated a significant clinical benefit in terms of time to progression, and of overall survival in one of the two studies, for some patients with higher-risk SMM treated with lenalidomide ± dexamethasone, raising the question of whether such an approach should be considered a new standard of care. In this paper, experts from the European Myeloma Network describe current biological and clinical knowledge on SMM, focusing on novel insights into its molecular pathogenesis, new prognostic scoring systems proposed to identify SMM patients at higher risk of early transformation, and updated results of completed or ongoing clinical trials. Finally, some practical recommendations for the real-life management of these patients, based on Delphi consensus methodology, are provided.
The advances in cancer immunotherapy come with several obstacles, limiting its widespread use and benefits so far only to a small subset of patients. One of the underlying challenges remains to be the lack of representative nonclinical models that translate to human immunity and are able to predict clinical efficacy and safety outcomes. In recent years, immunocompetent Cancer-on-Chip models emerge as an alternative human-based platform that enables the integration and manipulation of complex tumor microenvironment. In this review, we discuss novel opportunities offered by Cancer-on-Chip models to advance (mechanistic) immuno-oncology research, ranging from design flexibility to multimodal analysis approaches. We then exemplify their (potential) applications for the research and development of adoptive cell therapy, immune checkpoint therapy, cytokine therapy, oncolytic virus, and cancer vaccines.
Background
In the phase 3 ALCYONE study, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) versus bortezomib/melphalan/prednisone (VMP) significantly improved progression-free survival (PFS) and overall survival (OS) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients. We present a subgroup analysis of ALCYONE by patient frailty status.
Patients and Methods
Frailty assessment was performed retrospectively using age, Charlson comorbidity index, and baseline Eastern Cooperative Oncology Group performance status score. Patients were classified as fit (0), intermediate (1), or frail (≥2); a nonfrail category combined fit and intermediate patients.
Results
Among randomized patients (D-VMP, n = 350; VMP, n = 356), 391 (55.4%) were nonfrail (D-VMP, 187 [53.4%]; VMP, 204 [57.3%]) and 315 (44.6%) were frail (163 [46.6%]; 152 [42.7%]). After 40.1-months median follow-up, nonfrail patients had longer PFS and OS than frail patients, but benefits of D-VMP versus VMP were maintained across subgroups: PFS nonfrail (median, 45.7 vs. 19.1 months; hazard ratio [HR], 0.36; P < .0001), frail (32.9 vs. 19.5 months; HR, 0.51; P < .0001); OS nonfrail (36-month rate, 83.6% vs. 74.5%), frail (71.4% vs. 59.0%). Improved greater than or equal to complete response and minimal residual disease (10−5)-negativity rates were observed for D-VMP versus VMP across subgroups. The 2 most common grade 3/4 treatment-emergent adverse events were neutropenia (nonfrail: 39.2% [D-VMP] and 42.4% [VMP]; frail: 41.3% and 34.4%) and thrombocytopenia (nonfrail: 32.8% and 36.9%; frail: 36.9% and 39.1%).
Conclusion
Our findings support the clinical benefit of D-VMP in transplant-ineligible NDMM patients enrolled in ALCYONE, regardless of frailty status.
Emerging data demonstrate that the activity of immune cells can be modulated by microbial molecules. Here, we show that the short-chain fatty acids (SCFAs) pentanoate and butyrate enhance the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells through metabolic and epigenetic reprograming. We show that in vitro treatment of CTLs and CAR T cells with pentanoate and butyrate increases the function of mTOR as a central cellular metabolic sensor, and inhibits class I histone deacetylase activity. This reprogramming results in elevated production of effector molecules such as CD25, IFN-γ and TNF-α, and significantly enhances the anti-tumor activity of antigen-specific CTLs and ROR1-targeting CAR T cells in syngeneic murine melanoma and pancreatic cancer models. Our data shed light onto microbial molecules that may be used for enhancing cellular anti-tumor immunity. Collectively, we identify pentanoate and butyrate as two SCFAs with therapeutic utility in the context of cellular cancer immunotherapy.
Background
Gastric pull-up (GPU) procedures may be complicated by leaks, fistulas, or stenoses. These complications are usually managed by endoscopy, but in extreme cases multidisciplinary management including reoperation may be necessary. Here, we report a combined endoscopic and surgical approach to manage a failed secondary GPU procedure.
Case summary
A 70-year-old male with treatment-refractory cervical esophagocutaneous fistula with stenotic remnant esophagus after secondary GPU was transferred to our tertiary hospital. Local and systemic infection originating from the infected fistula was resolved by endoscopy. Hence, elective esophageal reconstruction with free-jejunal interposition was performed with no subsequent adverse events.
Conclusion
A multidisciplinary approach involving interventional endoscopists and surgeons successfully managed severe complications arising from a cervical esophago-cutaneous fistula after GPU. Endoscopic treatment may have lowered the perioperative risk to promote primary wound healing after free-jejunal graft interposition.
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.
We compared the feasibility of 4 cytomegalovirus (CMV)- and Aspergillus-reactive T-cell immunoassay protocols in allogenic stem cell transplant recipients. While enzyme-linked immunospot performed best overall, logistically advantageous whole blood–based assays performed comparably in patients with less severe lymphocytopenia. CMV-induced interferon-gamma responses correlated strongly across all protocols and showed high concordance with serology.
Purpose
The ongoing pandemic caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2) has stressed health systems worldwide. Patients with chronic kidney disease (CKD) seem to be more prone to a severe course of coronavirus disease (COVID-19) due to comorbidities and an altered immune system. The study’s aim was to identify factors predicting mortality among SARS-CoV-2-infected patients with CKD.
Methods
We analyzed 2817 SARS-CoV-2-infected patients enrolled in the Lean European Open Survey on SARS-CoV-2-infected patients and identified 426 patients with pre-existing CKD. Group comparisons were performed via Chi-squared test. Using univariate and multivariable logistic regression, predictive factors for mortality were identified.
Results
Comparative analyses to patients without CKD revealed a higher mortality (140/426, 32.9% versus 354/2391, 14.8%). Higher age could be confirmed as a demographic predictor for mortality in CKD patients (> 85 years compared to 15–65 years, adjusted odds ratio (aOR) 6.49, 95% CI 1.27–33.20, p = 0.025). We further identified markedly elevated lactate dehydrogenase (> 2 × upper limit of normal, aOR 23.21, 95% CI 3.66–147.11, p < 0.001), thrombocytopenia (< 120,000/µl, aOR 11.66, 95% CI 2.49–54.70, p = 0.002), anemia (Hb < 10 g/dl, aOR 3.21, 95% CI 1.17–8.82, p = 0.024), and C-reactive protein (≥ 30 mg/l, aOR 3.44, 95% CI 1.13–10.45, p = 0.029) as predictors, while renal replacement therapy was not related to mortality (aOR 1.15, 95% CI 0.68–1.93, p = 0.611).
Conclusion
The identified predictors include routinely measured and universally available parameters. Their assessment might facilitate risk stratification in this highly vulnerable cohort as early as at initial medical evaluation for SARS-CoV-2.
Objective
The current article encompasses a literature review and recommendations for radiotherapy in nodal oligorecurrent prostate cancer.
Materials and methods
A literature review focused on studies comparing metastasis-directed stereotactic ablative radiotherapy (SABR) vs. external elective nodal radiotherapy (ENRT) and studies analyzing recurrence patterns after local nodal treatment was performed. The DEGRO Prostate Cancer Expert Panel discussed the results and developed treatment recommendations.
Results
Metastasis-directed radiotherapy results in high local control (often > 90% within a follow-up of 1–2 years) and can be used to improve progression-free survival or defer androgen deprivation therapy (ADT) according to prospective randomized phase II data. Distant progression after involved-node SABR only occurs within a few months in the majority of patients. ENRT improves metastases-free survival rates with increased toxicity in comparison to SABR according to retrospective comparative studies. The majority of nodal recurrences after initial local treatment of pelvic nodal metastasis are detected within the true pelvis and common iliac vessels.
Conclusion
ENRT with or without a boost should be preferred to SABR in pelvic nodal recurrences. In oligometastatic prostate cancer with distant (extrapelvic) nodal recurrences, SABR alone can be performed in selected cases. Application of additional systemic treatments should be based on current guidelines, with ADT as first-line treatment for hormone-sensitive prostate cancer. Only in carefully selected patients can radiotherapy be initially used without additional ADT outside of the current standard recommendations. Results of (randomized) prospective studies are needed for definitive recommendations.